Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

References

• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931-59; PMID:11497241; http://dx.doi.org/10.1007/PL00000912
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62; PMID:990323; http://dx.doi.org/10.1016/0005-2736(76)90160-7
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-85; PMID:14576852; http://dx.doi.org/10.1038/sj.onc.1206948
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58; PMID:11902585; http://dx.doi.org/10.1038/nrc706
   PubMed Web of Science ®Google Scholar
• Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010; 126: 545-62; PMID:19609946; http://dx.doi.org/10.1002/ijc.24750
   PubMed Web of Science ®Google Scholar
• McCawley LJ, Li S, Wattenberg EV, Hudson LG. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999; 274: 4347-53; PMID:9933637; http://dx.doi.org/10.1074/jbc.274.7.4347
   PubMed Web of Science ®Google Scholar
• Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A 1999; 96: 1415-20; PMID:9990038; http://dx.doi.org/10.1073/pnas.96.4.1415
   PubMed Web of Science ®Google Scholar
• Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294-7; PMID:15549090; http://dx.doi.org/10.1038/nature03095
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-9; PMID:16002463; http://dx.doi.org/10.1124/jpet.105.084145
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-7; PMID:15059881; http://dx.doi.org/10.1158/0008-5472.CAN-03-3344
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Jr., Chen X, Chen ZS. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009; 78: 153-61; PMID:19427995; http://dx.doi.org/10.1016/j.bcp.2009.04.002
   PubMed Web of Science ®Google Scholar
• Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Yabuuchi H, Soda H, Kohno S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 2005; 49: 337-43; PMID:15955594; http://dx.doi.org/10.1016/j.lungcan.2005.03.035
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67: 11012-20; PMID:18006847; http://dx.doi.org/10.1158/0008-5472.CAN-07-2686
   PubMed Web of Science ®Google Scholar
• Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008; 68: 7905-14; PMID:18829547; http://dx.doi.org/10.1158/0008-5472.CAN-08-0499
   PubMed Web of Science ®Google Scholar
• Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 2009; 4: e5172
   PubMed Web of Science ®Google Scholar
• Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 2009; 64: 961-9; PMID:19255759; http://dx.doi.org/10.1007/s00280-009-0949-1
   PubMed Web of Science ®Google Scholar
• Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Kéri G, Katona M, Takáts Z, Váradi A, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158: 1153-64; PMID:19785662; http://dx.doi.org/10.1111/j.1476-5381.2009.00383.x
   PubMed Web of Science ®Google Scholar
• Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009; 279: 74-83; PMID:19232821; http://dx.doi.org/10.1016/j.canlet.2009.01.027
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-61; PMID:15615512; http://dx.doi.org/10.1021/jm049486a
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401; PMID:15256671; http://dx.doi.org/10.1126/science.1099480
   PubMed Web of Science ®Google Scholar
• Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-308; PMID:18158072; http://dx.doi.org/10.1016/j.clinthera.2007.11.005
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-41; PMID:16775234; http://dx.doi.org/10.1056/NEJMoa055229
   PubMed Web of Science ®Google Scholar
• Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009; 330: 956-63; PMID:19491323; http://dx.doi.org/10.1124/jpet.109.154781
   PubMed Web of Science ®Google Scholar
• Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011; 17: 6905-13; PMID:22028489; http://dx.doi.org/10.1158/1078-0432.CCR-11-0288
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng Q, Wang C, Liu Q, Huo X, Zhang A, Sun P, Sun H, Li H, Liu K. Methotrexate-bestatin interaction: Involvement of P-glycoprotein and organic anion transporters in rats. Int J Pharm 2014; 465: 368-77; PMID:24530518; http://dx.doi.org/10.1016/j.ijpharm.2014.02.020
   PubMed Web of Science ®Google Scholar
• Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013; 339: 107-15; PMID:23879965; http://dx.doi.org/10.1016/j.canlet.2013.07.016
   PubMed Web of Science ®Google Scholar
• Zhou WJ, Zhang X, Cheng C, Wang F, Wang XK, Liang YJ, To KK, Zhou W, Huang HB, Fu LW. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 2012; 166: 1669-83; PMID:22233293; http://dx.doi.org/10.1111/j.1476-5381.2012.01849.x
   PubMed Web of Science ®Google Scholar
• Huo X, Liu Q, Wang C, Meng Q, Sun H, Peng J, Ma X, Liu K. Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. Eur J Pharm Sci 2013; 50: 420-8; PMID:23981338; http://dx.doi.org/10.1016/j.ejps.2013.08.010
   PubMed Web of Science ®Google Scholar
• Wang L, Meng Q, Wang C, Liu Q, Peng J, Huo X, Sun H, Ma X, Liu K. Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-kappaB signaling inhibition. J Nat Prod 2013; 76: 909-14; PMID:23621869; http://dx.doi.org/10.1021/np400071c
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96; PMID:18287387; http://dx.doi.org/10.3322/CA.2007.0010
   PubMed Web of Science ®Google Scholar
• Rous PA. Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells. J Exp Med 1911; 13: 397-411; PMID:19867421; http://dx.doi.org/10.1084/jem.13.4.397
   PubMedGoogle Scholar
• Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992; 52: 4773-8; PMID:1380891
   PubMed Web of Science ®Google Scholar
• Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res 1983; 43: 1696-702; PMID:6403227
   PubMed Web of Science ®Google Scholar
• Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 1994; 14: 735-43; PMID:7903421
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-26; PMID:17268817; http://dx.doi.org/10.1007/s10549-006-9463-x
   PubMed Web of Science ®Google Scholar
• Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010; 70: 2296-306; PMID:20215510; http://dx.doi.org/10.1158/0008-5472.CAN-09-3141
   PubMed Web of Science ®Google Scholar
• Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648-55; PMID:16740702; http://dx.doi.org/10.1158/0008-5472.CAN-06-0734
   PubMed Web of Science ®Google Scholar
• Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095-105; PMID:17700528; http://dx.doi.org/10.1038/sj.onc.1210714
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM. MicroRNA-26b suppresses the NF-kappaB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer 2014; 13: 35; PMID:24565101; http://dx.doi.org/10.1186/1476-4598-13-35
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 1998; 95: 7024-9; PMID:9618532; http://dx.doi.org/10.1073/pnas.95.12.7024
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-85; PMID:9920858
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997; 36: 11169-78; PMID:9287159; http://dx.doi.org/10.1021/bi9627830
   PubMed Web of Science ®Google Scholar
• Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR, Krusch M. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-28; PMID:20143399; http://dx.doi.org/10.1002/ijc.25233
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011; 117: 1947-57; PMID:21148814; http://dx.doi.org/10.1182/blood-2010-06-291146
   PubMed Web of Science ®Google Scholar
• Wei N, Liu GT, Chen XG, Liu Q, Wang FP, Sun H. H1, a derivative of Tetrandrine, exerts anti-MDR activity by initiating intrinsic apoptosis pathway and inhibiting the activation of Erk1/2 and Akt1/2. Biochem Pharmacol 2011; 82: 1593-603; PMID:21864508; http://dx.doi.org/10.1016/j.bcp.2011.08.012
   PubMed Web of Science ®Google Scholar
• Oh SY, Song JH, Gil JE, Kim JH, Yeom YI, Moon EY. ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp Cell Res 2006; 312: 1651-7; PMID:16515784; http://dx.doi.org/10.1016/j.yexcr.2006.01.030
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84; PMID:17126425; http://dx.doi.org/ 10.1016/j.bbamcr.2006.10.001
   PubMed Web of Science ®Google Scholar